文献速递物质与行为成瘾

阿片类使用障碍药物治疗期间过量事件风险

Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder.
PubMed 文献 · Am J Psychiatry · 2023-03-09

该研究整合三项阿片类使用障碍药物治疗(MOUD)随机试验共2199例患者的不良事件数据,采用生存分析比较24周内过量事件风险。结果显示,未启动或停用研究药物者及基线使用苯二氮䓬类药物者过量事件风险显著升高,而纳曲酮组在控制依从性后未见显著效应。

要点

  • 未启动或停用MOUD者过量风险显著升高,HR分别为6.64和4.04。
  • 基线苯二氮䓬使用与过量风险升高相关(HR=3.36)。
  • 控制依从性后,纳曲酮组过量风险无显著差异。

核心结论

  • 在寻求药物治疗的阿片类使用障碍患者中,未启动或停用药物及基线苯二氮䓬使用者的24周过量事件风险升高。

研究设计与样本

  • 整合三项MOUD务实临床试验(N=2199)的不良事件日志,采用含时间依赖协变量的Cox比例风险模型进行生存分析。

主要发现

  • 24周内39例发生至少一次过量事件;纳曲酮组15例(5.30%),美沙酮组8例(1.51%),丁丙诺啡组16例(1.15%)。
  • 缓释纳曲酮组27.9%未启动药物,其过量率为8.9%(7/79),启动者过量率为3.9%(8/204)。
  • 控制社会人口学、时间依赖服药依从性及基线物质使用后,纳曲酮分配无显著效应。
  • 基线苯二氮䓬使用(HR=3.36,95%CI=1.76-6.42)、从未启动研究药物(HR=6.64,95%CI=2.12-19.54)及启动后停药(HR=4.04,95%CI=1.54-10.65)与过量风险升高显著相关。

临床怎么用

  • 临床应关注MOUD患者的药物启动与持续依从性,未启动或停药者需加强监测与干预。
  • 对基线使用苯二氮䓬类药物的MOUD患者应评估过量风险并加强管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Overdose risk during a course of treatment with medication for opioid use disorder (MOUD) has not been clearly delineated. The authors sought to address this gap by leveraging a new data set from three large pragmatic clinical trials of MOUD. METHODS: Adverse event logs, including overdose events, from the three trials (N=2,199) were harmonized, and the overall risk of having an overdose event in the 24 weeks after randomization was compared for each study arm (one methadone, one naltrexone, and three buprenorphine groups), using survival analysis with time-dependent Cox proportional hazard models. RESULTS: By week 24, 39 participants had ≥1 overdose event. The observed frequency of having an overdose event was 15 (5.30%) among 283 patients assigned to naltrexone, eight (1.51%) among 529 patients assigned to methadone, and 16 (1.15%) among 1,387 patients assigned to buprenorphine. Notably, 27.9% of patients assigned to extended-release naltrexone never initiated the medication, and their overdose rate was 8.9% (7/79), compared with 3.9% (8/204) among those who initiated naltrexone. Controlling for sociodemographic and time-varying medication adherence variables and baseline substance use, a proportional hazard model did not show a significant effect of naltrexone assignment. Significantly higher probabilities of experiencing an overdose event were observed among patients with baseline benzodiazepine use (hazard ratio=3.36, 95% CI=1.76, 6.42) and those who either were never inducted on their assigned study medication (hazard ratio=6.64, 95% CI=2.12, 19.54) or stopped their medication after initial induction (hazard ratio=4.04, 95% CI=1.54, 10.65). CONCLUSIONS: Among patients with opioid use disorder seeking medication treatment, the risk of overdose events over the next 24 weeks is elevated among those who fail to initiate or discontinue medication and those who report benzodiazepine use at baseline.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Brandt L, Hu MC, Liu Y, et al. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. Am J Psychiatry. 2023. PMID: 36891640. doi:10.1176/appi.ajp.20220312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。